Get the Stockscreener App
1.75
8.02%
0.13
After Hours:
1.82
0.07
+4.00%
Gain Therapeutics Inc stock is traded at $1.75, with a volume of 691.85K.
It is up +8.02% in the last 24 hours and down -31.37% over the past month.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
See More
Previous Close:
$1.62
Open:
$1.63
24h Volume:
691.85K
Relative Volume:
0.49
Market Cap:
$67.31M
Revenue:
$210.70K
Net Income/Loss:
$-21.37M
P/E Ratio:
-1.5909
EPS:
-1.1
Net Cash Flow:
$-21.10M
1W Performance:
-2.78%
1M Performance:
-31.37%
6M Performance:
+13.27%
1Y Performance:
-33.71%
1-Day Range:
$1.63
$1.82
1-Week Range:
$1.61
$1.9492
52-Week Range:
$1.41
$4.34
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.75 | 62.31M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
Critical Contrast: Gain Therapeutics (NASDAQ:GANX) and Ionis Pharmaceuticals (NASDAQ:IONS) - Defense World
Gain Therapeutics, Inc Advances Parkinson's Treatment to Phase 2 - TradingView
Treasury Yields: What hedge funds are buying Gain Therapeutics IncMarket Growth Report & Long-Term Safe Return Strategies - baoquankhu1.vn
Smart Money: Is Gain Therapeutics Inc part of any major index2025 Buyback Activity & Risk Controlled Daily Plans - baoquankhu1.vn
Is Pediatrix Medical Group Inc. stock undervalued right nowJuly 2025 Breakouts & Technical Confirmation Alerts - baoquankhu1.vn
Published on: 2026-01-31 20:42:39 - baoquankhu1.vn
Wall Street Recap: Can Gain Therapeutics Inc outperform in the next rallyTrade Performance Summary & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
5 Investigational Therapies That Could Change the Parkinson’s Landscape - BioSpace
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Bond Watch: Will Atlantica Sustainable Infrastructure plc stock benefit from M AMarket Growth Review & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Aug Final Week: Should I average down on Gain Therapeutics Inc stockNew Guidance & Safe Entry Trade Signal Reports - baoquankhu1.vn
Can Gain Therapeutics Inc. stock attract ESG capital inflowsVolatility Adjusted Trading & Free Stay Informed With Forecasts - Bollywood Helpline
Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Rises By 28.6% - MarketBeat
Aug PreEarnings: Can Gain Therapeutics Inc continue delivering strong returnsJuly 2025 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Exit Recap: Is Gain Therapeutics Inc attractive for institutional investors2025 Breakouts & Breakdowns & Weekly Watchlist of Top Performers - baoquankhu1.vn
Wall Street Recap: Is Gain Therapeutics Inc trading at a discountWeekly Earnings Recap & Consistent Profit Trading Strategies - baoquankhu1.vn
Pullback Watch: What is Gain Therapeutics Incs 5 year growth outlookTrade Volume Summary & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Movement Recap: Can Gain Therapeutics Inc outperform in the next rallyJuly 2025 Spike Watch & Free Verified High Yield Trade Plans - baoquankhu1.vn
Aug Fed Impact: Whats the beta of Gain Therapeutics Inc stockMarket Activity Recap & Fast Entry and Exit Trade Plans - baoquankhu1.vn
EPS Watch: Whats the beta of Gain Therapeutics Inc stock2025 EndofYear Setup & Short-Term High Return Strategies - baoquankhu1.vn
Aug Intraday: What is Gain Therapeutics Incs TAM Total Addressable MarketJuly 2025 Breakouts & Daily Profit Focused Stock Screening - baoquankhu1.vn
Why Gain Therapeutics Inc. stock could see breakout soonQuarterly Risk Review & Free Technical Pattern Based Buy Signals - Улправда
Gain Therapeutics Shares Early Phase 1b Data: GT-02287 Shows UPDRS Gains, Key PD Biomarker Drop - Defense World
Reviewing Aldeyra Therapeutics (NASDAQ:ALDX) & Gain Therapeutics (NASDAQ:GANX) - Defense World
How Ideal Power Inc. (5ILA) stock gains from tech spendingJuly 2025 Trade Ideas & Risk Controlled Swing Alerts - Улправда
Will Stoke Therapeutics Inc. stock gain from strong economyJuly 2025 Trends & Verified Short-Term Trading Plans - Улправда
Is Zentalis Pharmaceuticals Inc. stock ready for breakoutGap Up & Low Risk Profit Maximizing Plans - Улправда
Is Gain Therapeutics Inc. stock supported by strong fundamentalsJuly 2025 Momentum & Low Risk Growth Stock Ideas - Улправда
Why Gain Therapeutics Inc. stock attracts high net worth investorsDollar Strength & Risk Controlled Daily Plans - Улправда
Published on: 2026-01-09 02:02:08 - Улправда
Stock Recap: Why Gain Therapeutics Inc. stock attracts high net worth investorsEarnings Overview Summary & Verified Momentum Stock Watchlist - Улправда
Can Gain Therapeutics Inc. stock reach $100 price target2025 Earnings Surprises & Daily Profit Maximizing Tips - Улправда
Gain Therapeutics provides additional data from Phase 1b study of GT-02287 - MSN
Gain Therapeutics reports 81% reduction in Parkinson’s biomarker By Investing.com - Investing.com Nigeria
Gain Therapeutics, Inc. to Participate in Key Events During 44th Annual J.P. Morgan Healthcare Conference Week - Quiver Quantitative
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week - The Manila Times
Biotech firm Gain Therapeutics lines up three events in San Francisco - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
GANX: GT-02287 reduced GluSph by 81% and improved motor scores in Parkinson's disease patients - TradingView — Track All Markets
Gain Therapeutics reports 81% reduction in Parkinson’s biomarker - Investing.com
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 - The Manila Times
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update - MarketBeat
Research Analysts’ Weekly Ratings Changes for Gain Therapeutics (GANX) - Defense World
GT-02287 boosts enzyme activity in Parkinson’s brain: Trial data - Parkinson's News Today
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why - Yahoo Finance
Roth/MKM raises Gain Therapeutics stock price target to $10 on positive trial data - Investing.com Canada
Roth/MKM raises Gain Therapeutics stock price target to $10 on positive trial data By Investing.com - Investing.com South Africa
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):